Spravato Billing Services
We collect the costs associated with the drug, its delivery, and two-hour costs for esketamine through FDA REMS. The esketamine claim denial codes consist of old codes, unit mismatch, and bundled codes problems. The codes we use are in line with the 2026 code set for Medicare, Medicaid, and commercial insurance plans.
J0013 Substituted for S0013 from non-Medicare carriers effective January 1, 2026
G2082 / G2083 Bundled Medicare code for established patient visits
2-hour REMS Attached observation form with all claims
Enter Your Details
What Is Spravato Billing?
The Spravato reimbursement process is a specialty medication that uses a specialty billing process with three separately billable items all appearing on the same form. This includes its own HCPCS code, the encounter’s evaluation and management code, and the two-hour observation that can be billed in minutes. Since each element has a unique insurance requirement, a single claim contains reimbursement policy, medical policy, and REMS documentation for a single pharmaceutical drug.
This bifurcates based on the type of insurance prior to selection of a single code. Under the buy and bill process, patients covered by Medicare are paid using G codes which bundle the drug, visit, and observation as one payment. For Medicaid and commercial insurance, there are two distinct codes for the drug and the professional time separately. Most rejections of a Spravato claim arise due to incorrect split.
Drug coding
J0013 for payers other than Medicare in units of 1 mg, or bundle of G codes for Medicare patients.
Observation
Billing is done separately or bundled according to the payer pathway.
Administration
Coded according to the status of the patient and payer pathway, new or established.
REMS documentation
REMS certification and observation notes document medical necessity of the claim.
What Is Spravato (Esketamine)?
“Spravato” is a medication known as esketamine, which is used in a licensed healthcare setting via nasal spray. It is an NMDA receptor blocker approved by the FDA for depression resistant to other forms of treatment in the form of monotherapy on January 21, 2025. In addition, the medicine is used for the treatment of depressive symptoms in people with major depressive disorders and suicidality. Among the indications for taking the drug include sedation, dissociation, respiratory depression, abuse, and suicidality. That is why two hours of observation after administering the drug is necessary.
Spravato Billing Codes for 2026 (J0013, G2082, G2083)
Codes used for Spravato billing were updated from January 1, 2026. The temporary code, which was being used to indicate the use of esketamine from its launch till date, i.e., S0013 was discontinued by CMS and was replaced by the new HCPCS code J0013.
| Code | Descriptor | Pathway & status |
|---|---|---|
| J0013 | Esketamine, nasal spray, 1 mg | Medicaid, commercial, other non-Medicare. Non-payable by Medicare. Replaced S0013. |
| S0013 | Esketamine, nasal spray, 1 mg | Discontinued by CMS effective Jan 1, 2026. Do not submit for current dates of service. |
| G2082 | Visit + esketamine up to 56 mg + 2-hour observation, bundle | Medicare buy-and-bill; established patients only. |
| G2083 | Visit + esketamine above 56 mg + 2-hour observation, bundle | Medicare buy-and-bill; established patients only. |
| J3490 | Drugs without classification | A transitional backup for when a payer has not yet entered J0013 |
J0013-Esketamine, nasal spray, 1 mg
J0013 coding procedure for Spravato needs to be done where the drug is billed under Medicaid, Commercial, and all other plans except Medicare. The number of units needs to correspond with the total dosage of the medicine in milligrams administered to the patient. If the dosage of the medicine is 56 mg, then the units will be 56 and similarly if 84 mg, the units will be 84.
G2082 & G2083-Medicare Bundled Session Codes
For Medicare patients using the buy-and-bill billing process, G2082 applies to visits where there is an administration of up to 56 mg of esketamine. G2083 applies to visits where there is an administration of more than 56 mg of esketamine. Codes G2082 and G2083 include payment for the medication, E&M visit, and mandatory two hours of observation in one bill. There are two limitations when filing a claim using these codes. The codes are limited to established patients. Codes 99417 or G2212 can't be on the same claim.
J3490-Transitional Fallback
In situations where a payer has not yet entered code J0013 into their system, J3490 is used to denote unclassified drugs. The claim shows the name of the drug, the NDC, dose, and route from the notes.
New Patients Follow A Different Rule
G2082 and G2083 are codes for established patients. For a new patient, his or her first visit would be coded under E/M codes, while G codes would be used after the patient becomes established. The billing of G code on the first visit is one of the major reasons.
E/M Codes and Prolonged Services Codes for Non-Bundled Claims
Some of the visits may involve providing medication by the pharmacy and billing only professional services by the doctor’s office. This particular visit may be charged through the right codes. New patients should use 99202 through 99205, whereas established patients should use 99211 through 99215. Observation periods which exceed the E/M threshold can be captured using prolonged service codes. 99417 can be used for commercial payers and G2212 for Medicare. Clinical staff use codes 99415 and 99416.
ICD-10 Codes That Support Medical Necessity
Payer validation of the Spravato claims will be done according to the diagnosis code for the treatment-resistant depression and major depressive disorder. The R45.851 code applies for the suicidal ideation that meets the MDSI indication. Payer will confirm if the actual code matches CMS article A59249 Group 1.
Buy-and-Bill vs. Specialty Pharmacy Billing
The selection of the model determines which code set is used prior to constructing the claim.
| Model A Buy-and-Bill | Model B Specialty Pharmacy |
|---|---|
| The physician buys esketamine and keeps it in stock. Then the practice files the claim for both the drug and the procedure. Medicare patients go through the bundling process using G codes. The cost of drug stock remains with the practice until the payment from the claim, and thus the denial results in a loss of both drug cost and visit. | The drug is dispensed by the specialty pharmacy certified by REMS, and the pharmacy files a separate claim with J0013. The practice files claims for E/M and observation separately. The risk of having the drug in stock stays with the pharmacy and not the practice. Some payers mandate this approach. |
Payers police the split
Professional billing for 2026 should be performed under code G2082 or G2083, and unbilled services should not be performed using codes J0013 or J3490. J0013 coding is used in the Highmark policy provided that specialty pharmacies dispense the medication by themselves.
Spravato Reimbursement Rates
The Medicare rate for the G codes is determined by the Medicare Physician Fee Schedule and is adjusted for locality. Commercial rates are negotiated and therefore two plans could have a different payment for the 84 mg procedure. The rate was further altered when the code change occurred and some providers have seen a reduced rate for J0013 as compared to the S0013. Make sure you know the rate for J0013 in your payer contracts before writing the difference off.
The part B and part D routing makes things more complex still. The esketamine treatment when delivered in a certified clinic by way of buy and bill routes through the G codes under part B. It is not routed through part D using this method although the Medicare Advantage plans vary widely.
The Spravato Billing Process
Each step serves to eliminate a particular denial before submission of the claim from the practice.
Eligibility & benefit routing
We determine whether the patient is covered under Part B buy-and-bill, Medicaid, or private health insurance. Benefit routing determines the code set; therefore, it comes before coding.
Prior authorization to the current designation
The prior authorization is prepared according to the monotherapy 2025 approval rather than the two antidepressants rule that has been phased out. Any PA referencing S0013 will be reissued before the first 2026 claim.
REMS validation
We first verify the certificate and registration of the clinic before submitting the claim. The absence of REMS documents could be the grounds for denial recorded in the system.
Dose-driven code selection
We correlate the code with the number of milligrams that were given. Dose dictates use of G2082 versus G2083 for Medicare and determines the units on J0013 for non-Medicare.
Observation documentation
We include the documentation of the two-hour observation with its start and end times. The observation is submitted individually or unbundled according to the payer flow.
Claim filing and appeal
We file the claim with the appropriate NDC when required and monitor the claim until payment. We appeal denials with the observation report and PA documentation.
Why Spravato Billing Requires Specialized Expertise
It is a specialty drug reimbursement process that requires REMS documentation, a dual code structure, and payer policy tracking. There are four differences between it and an ordinary claim.
Dual code structure
While Medicare combines the visit in one G code, other payers break the treatment into the drug and visit. The patient panel will have two different coding mechanisms at once.
REMS documentation
Esketamine is in a closed FDA REMS program. The certification and observation information comes with the claim, rather than chart.
Live code transition
The transition from S0013 to J0013 is being rolled out. The payer systems and authorizations are behind on the transition, causing different payment outcomes using the same code.
High risk for denials
Each denial reason such as retired code, unit mismatch, and improper use of a bundled code leads to denial. Every visit can have multiple thousands at stake.
Common Spravato Billing Challenges
There exists a distinct reason for denying each scenario discussed below rather than a problem concerning the basic principles of coding.
| Billing Challenges | Description |
|---|---|
| Denial reasons for retired code | Procedure code S0013 for date of service 2026 is an invalid procedure code. The PA coded in 2025 as S0013 will automatically result in the denial process in the event that the claim contains the procedure code J0013. |
| Discrepancies between the unit and NDC | The units of J0013 must always equal the total amount of milligrams, and the 11-digit NDC is required for Medicaid claims. Any discrepancy within the unit count or lack of NDC will automatically result in rejection. |
| Codes prolonged with G codes | The coding of 99417 or G2212 together with G2082 or G2083 leads to double counting of observation time, because observation itself is part of the bundle. |
| Authorization Expired | Many insurance plans get their authorizations renewed after every three months. Authorization that expires while treatment is ongoing is one of the most common denials that can be avoided. |
| Documentation of observation is lacking | When there are no start and end times for the two hours period of the authorization, then the medical necessity is not met. The monitoring sheet is the proof. |
| Risk of clawback | In buy and bill cases, the office possesses the medicine before billing takes place. Clawbacks refer to money that has been spent. |
How to Avoid Spravato Billing Errors
Fix The Code And Units First
Verify that all of your top payers want J0013, S0013 grace, or J3490 as of the claim date.
Change units on J0013 claims to equal milligram dose in every non-Medicare claim.
Every active PA that still uses the retired code before billing.
Observation Note To The Minute
Make sure that the time of starting and ending of two hours is documented with vitals.
Affix 11-digit NDC number on Medicaid or dual eligible claim for J0013.
Keep a record of REMS enrollment documentation for every date of service.
Match the Code to the Patient and Dose
Use G2082 and G2083 only for established patients and use E/M services on initial visits.
G2082 to G2083 based on the actual dose given during that visit.
Do not include prolonged service codes on any claims that have bundled G codes
Include appeals in the process
Submit an appeal with an observation note along with PA on the same claim
Keep track of reauthorization dates so that the patient does not miss during treatment.
Ensure that the rate associated with J0013 is included in the contract.
In-House vs. Outsourced Spravato Billing
The comparison below turns on esketamine-specific tasks, not general billing volume.
| Task | In-house team | UControl Billing |
|---|---|---|
| 2026 code transition | Monitors switch from S0013 to J0013 with care tasks. | Track when each payer adopted their policy and amend claims prior to denial. |
| Payer-by-payer rules | Determines position of each plan individually as denials come in. | Puts into effect the payer practice of unbundling like Highmark before submitting. |
| REMS records | Fills out certification and observation forms when time permits. | Ensures the eligibility and attaches observation documentation before submitting. |
| Appeals | Constructs documents again for each denial received. | Appeals using pre-submitted PA and monitoring information. |
Practices We Bill Spravato For
Psychiatry practices
Medication management practices using esketamine in treatment-resistant depression programs.
Behavioral health centers
Centers that have observation suites for supervision of two-hour visits.
Esketamine clinics
REMS-certified clinics providing a large amount of Spravato treatments under varied insurance panels.
Cost of Spravato Billing Services
The real cost has two components. Direct service fees are one component, and the other is the financial risk involved in mis-billing.
Direct fees
Fees for the service of billing are priced on a per case basis and stated in the proposal.
Financial risks associated with mis-billing
There are financial risks involved with mis-billing that do not show up on the invoice. The denial write-offs will be losses from revenue that has already been earned. The post-payment recovery
Performance Metrics That Matter for Spravato
There are four metrics that determine if an esketamine program bills properly.
First pass claim acceptance
Percentage of Spravato claims accepted on first pass. Retirement of the code and incorrect units are the most common reasons for the first pass rejection.
- read more
Claim denial rate by type
Type-based denials reveal whether the issue is with coding, PAs, or observation documents. The reason determines how it should be addressed.
- read more
Days in A/R
The number of days when Spravato claims is not yet paid. Carrying costs for drugs make A/R longer than average visits more expensive.
- read more
Reauthorizations on time
Percentage of active patients who receive renewed PA before it expires. The expired authorizations result in avoidable denials.
- read more
Our Credentials
We hold the certifications that payers and auditors look for, and our coders carry the right credentials. It’s not the most exciting part of the work, but it’s the part that keeps your claims on solid ground.
Explore Frequently Asked Questions
J0013 code took the place of S0013 starting from January 1, 2026, except for Medicare, who still use codes G2082 not more than 56 mg and G2083 more than 56 mg on their buy-and-bill claims. The bundled codes include the visit and two-hour drug observation period.
If Spravato is administered in a designated clinic using the buy-and-bill method, it is billed via Part B utilizing the G codes rather than Part D. However, benefit routing should be verified, as Medicare Advantage plans may have different designations.
In the buy-and-bill model, the medical practice buys the drug and bills both the drug and the services. In the specialty pharmacy model, the specialty pharmacy biller bills the drug separately on their own claim using J0013 and the medical practice bills only the visit and the observation period.
These include incorrect or outdated drug code, incorrect units or NDC, expiration of prior authorization, absence of observation records for REMS and long procedure codes in addition to G codes.
Yes, we monitor the certification of the clinic, ensure the enrollment of patient prior to the filing of the claim and attach two hour observation records to the claim. It is an FDA program, therefore it proves necessity as well as compliance.